Darshana Amin, DO
Neurology · Fort Myers, FLNPI 1407901382
Payments from drug & device makers
Across 89 payments — averaging $15.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$152
- Biohaven Pharmaceuticals, Inc.$150
- Sunovion Pharmaceuticals Inc.$80
- Adamas Pharmaceuticals, Inc.$70
- E.r. Squibb & Sons, L.L.C.$62
- SK Life Science, Inc.$58
- plus $811 from 27 others
What the payments were for
- Speaking & faculty fees$151%
- Food & beverage$1,37099%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 12 | $152 |
| Biohaven Pharmaceuticals, Inc. | 2 | $150 |
| Sunovion Pharmaceuticals Inc. | 7 | $80 |
| Adamas Pharmaceuticals, Inc. | 5 | $70 |
| E.r. Squibb & Sons, L.L.C. | 4 | $62 |
| SK Life Science, Inc. | 3 | $58 |
| UCB, Inc. | 4 | $56 |
| Amneal Pharmaceuticals LLC | 4 | $55 |
| Genentech USA, Inc. | 4 | $51 |
| Lilly USA, LLC | 4 | $50 |
| Novartis | 2 | $45 |
| Alnylam Pharmaceuticals Inc. | 3 | $44 |
| AbbVie(2 entities) | 3 | $43 |
| Merz North America, Inc. | 2 | $42 |
| MDD US Operations, LLC | 3 | $41 |
| Biogen | 3 | $39 |
| Amgen | 2 | $33 |
| Arbor Pharmaceuticals, Inc. | 2 | $30 |
| Jazz Pharmaceuticals Inc. | 2 | $29 |
| Eisai Inc. | 2 | $29 |
| Acadia Pharmaceuticals Inc | 2 | $26 |
| Supernus Pharmaceuticals, Inc. | 2 | $25 |
| Zyla Life Sciences, Inc. | 2 | $24 |
| CSL Behring | 1 | $17 |
| W. L. Gore & Associates, Inc. | 1 | $17 |
| Assertio Therapeutics, Inc. | 1 | $16 |
| Mallinckrodt Enterprises LLC | 1 | $15 |
| Kyowa Kirin, Inc. | 1 | $15 |
| Avanir Pharmaceuticals, Inc. | 1 | $15 |
| Acorda Therapeutics, Inc | 1 | $15 |
| Neurocrine Biosciences, Inc. | 1 | $14 |
| Upsher-smith Laboratories LLC | 1 | $14 |
| Portola Pharmaceuticals, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$125
How this compares
$1,384 in reported general payments places this provider in the 40th percentile of 1,434 neurology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other neurology in Fort Myers
- Wendy BondFort Myers$14.7M
- Mark GoldsteinAtlantis$36.1M
- Derrick RobertsonTampa$27.6M
- Beth SafirsteinHallandale Beach$25.7M
- Michael PfefferMiami$24.5M
- Mark BrodyDelray Beach$20.5M
- Paayal PatelWest Palm Beach$17.3M
- William HoneycuttMaitland$14.1M
- Julie SchwartzbardAventura$13.6M
- Rekha GandhiWinter Park$13.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.